Aurinia Pharmaceuticals Inc [AUPH] stock is trading at $13.17, saw in change for the day. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AUPH shares have gain 7.16% over the last week, with a monthly amount glided 16.04%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer downgraded its rating to Perform on November 04, 2022. Oppenheimer upgraded its rating to a Outperform and decreased its price target to $31 on December 10, 2021. Oppenheimer downgraded its rating to a Perform but $32 remained the price target by the analyst firm on October 28, 2021. H.C. Wainwright reiterated a Buy rating for this stock on January 25, 2021, and upped its price target to $35. In a note dated November 03, 2020, H.C. Wainwright reiterated a Buy rating on this stock and revised its target price from $34 to $28.
Aurinia Pharmaceuticals Inc [AUPH] stock has fluctuated between $6.55 and $13.54 over the past year. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] shares were valued at $13.17 at the most recent close of the market. An investor can expect a potential drop of -18.38% based on the average AUPH price forecast.
Analyzing the AUPH fundamentals
Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] reported sales of 260.11M for the trailing twelve months, which represents a growth of 22.41%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.24%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.17 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.81 points at the first support level, and at 12.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.51, and for the 2nd resistance point, it is at 13.85.
Ratios To Look Out For
For context, Aurinia Pharmaceuticals Inc’s Current Ratio is 5.23. Further, the Quick Ratio stands at 4.63, while the Cash Ratio is 0.68. Considering the valuation of this stock, the price to sales ratio is 6.66, the price to book ratio is 5.21 and price to earnings (TTM) ratio is 30.80.
Transactions by insiders
Recent insider trading involved TANG KEVIN, Director, that happened on Aug 01 ’25 when 1.0 million shares were purchased. Director, TANG KEVIN completed a deal on Aug 05 ’25 to buy 0.2 million shares. Meanwhile, Director TANG KEVIN bought 100000.0 shares on Aug 04 ’25.
